Extra-label drug use (ELDU) is needed to provide optimal therapy for ill dairy cattle. Proper ELDU requires cooperation and compliance between the veterinarian and producer to ensure that proper drug withdrawal times are observed. 
A Severe Case of Clinical Mastitis
This case is presented as a "real-life" situation in which the suitability and legality of therapy will follow. On August 21, a 6-year-old 1400 lb H olst ein co w 10 9 da ys in milk is presented with a temperature of 101.8°F, a heart rate of 92, a respiratory rate of 32, adequate rumen contractions, and a not iceably swollen but not hard quarter. She is 7-9% dehydrated, depressed, not eating, and not ket ot ic. U pon exam of her milk from the affected quar ter, there are many clots in the watery secretion. There are no other abnormalities present. T he first ste p in managing this cow would be to assess her severity level, which could easily be severe based on her elevated heart rate and her dehydrat ion. The next step would be to approach the management of this case with FANO (Fluids, Antibiotics, Non-steroidal ant i-inflammat or y, and Othe r). The co w is 7-9% dehydrated but still standing and t he rumen contractions seem normal. Administer 2 liters of 7% hypertonic saline followed by at least 12 ga llons of o ral fluids spiked with regular salt and diet salt. Because arou nd 30% of cows with sever e mastit is develop bacteria in the bloo dstream, use a good broad-spectrum antibiotic (Naxcel®). Then collect a milk sample for cult ure and treat intramammary (I MM) based on t he results of t he cult ure the fo llow ing d ay. Administer 15 ml o f an anti-inflammatory drug (Banamine®) intramuscularly (i.m.) and o ral a nd su bcut aneo us calcium.
The follo wing day E. coli grows as a lawn (colonies too numerous to count) on blood agar. The co w is re-evaluated the following morning and her temperat ure is now 104, pulse 94, respiratory rate 38, her rumen mot ility is still okay and she does not appear dehydrated. Continue the Naxcel at the labeled dose and repeat the Banamine. Treat her intramammary infusion with 6 ml of ceftiofur HCl (Excenel®) twice daily for 3 days . Flu ids w ere rep eat ed o n days 3 and 4. Banamine was repeated on day 3. Intramuscular Naxcel was continued through day 5.
Was My Clinical Mastitis
Therapy Legal?
Neither Naxcel nor Excenel have a label claim for treatment of clinical mastitis. Is there any ant ibiotic app roved fo r clinical mast itis or bacteria in the blood for treatment in lactating dairy cows? No, but ho w wo uld you find this information?
• Go to the website: htt p:/ /ww w.fd a.g ov/ cvm/ • Click on "Greenbook" • Click on "FDA Appro ved Animal Drug Pro duc ts O n-Line Database Syst em"
• Click on "Approved Animal Drug Products (Advanced)" • Type in the generic name of an antimicrobial and refine the search by adding a descriptor (e.g., amoxicillin and cattle). You could also enter mastitis. • For this example:
Field
Search Term Records All Fields amoxicillin and cat tle 4
• Now click on display records.
The only systemic use antibiotics with label indications for lactating dairy cat tle are amoxicillin, ampicillin, ceftiofur, erythromycin, oxytetracycline, penicillin, and sulfadimethoxine. None have label indications for clinical mastitis or bacteremia. Therefore, systemic antimicrobial therapy for treatment of clinical mast itis o r bactere mia is extralabel. Was it an acceptable ELDU?
Extralabel Drug Use (ELDU)
• ELDU is not permitted if a drug exists that is labeled for the food animal species and contains the needed ingredient, in the proper dosage form, labeled for the indication, and is clinically effective. Yes, an approved drug can be used ext ra-label.
C Proceed with Extra-label use of food animal drug.
C Establish extended withdrawal time. C Ensure fo od safe ty. C Maintain required records. C Label dr ug a ppr opriately.
Extralabel antimicrobial therapy must be prescribed only in accordance w ith t he Animal Medicinal Drug Use Clarification Act amendments to t he Food, Drug, and Cosmetic Act and its regulations (21 CFR Part 530). No drug can be marketed unless its qua lity, safety, and efficacy have been demonstrated. Thus, the first choice sho uld be based on the products approved for the species and the indication concerned. When no suit able pro duc t is a ppr ove d for a specific condition or species, or the approved product is considered t o be clinically ineffective, t he choice of an alternative pr oduct should be based, when possible, on the results o f valid scientific studies and a pr oven efficacy for the condition and species concerned (www. fda.go v/cvm/index/fdavet/2000/sept vet.htm). Based on ELDU guidelines and the algorithm, antimicrobials not labeled for lactating dair y cat tle but still le gal fo r us e in cat tle would be okay to use. However, it would seem prudent to use products that are approved for lact ating dairy catt le as the meat and milk withdrawal times have been scientifically validated.
When no approved drug is available or when higher-than-approved dosages of approved drugs are needed, vet erinarians must use the ir professional judgment regarding the benefits and risks to sick animals associated with extra-label use of drugs. Extra-label use for analgesic purposes is common because fe w animal-spec ific drugs have been approved for the relief of pain and suffering. Was use of Banamine extralabel and if so was its use appropriate? The answers to this are yes and yes. Anti-inflammatory drugs are often used to treat cases of clinical mastitis and none have a label claim specific for mastitis. However, our purpose in administering these drugs is to decrease fever, swelling, inflammation, and combat endotoxin. Based on reasons and listed indications in Table 1 , Banamine is an acceptable ELDU.
In the U.S., the only intramammary ant ibiot ic labeled for clinical mast itis is pirlimycin, which that has proven efficacy against staphylococcus and streptococcus species. Indications for some of the other intr amammary antibiotics imply clinical mast itis therapy but use words such as acute or chronic mastitis or administer at first signs of inflammat ion o r any alte rat ion in the milk. So was the use of intramammary ceftiofur HCL extralabel? Yes. But the use of intramammary ceftiofur HCl appears to be an appropriate ELDU because no approved and proven effective products for severe clinical coliform mastitis exist. But let's go a step further. Are there other requirement s?
One of the provisions the AVMA persuaded the Center for Veterinary Medicine (CVM) of the U.S. Food and Drug Administration (FDA) to include in its regulatio ns allows extralabel use when an approved drug is judg ed t o be clinically ineffective for its intended use. But what abou t ampicillin (Hetacin K) that has the only approved intramammary label claim against E. coli. I could not find a single st udy published in a peer-reviewed journal that r epor ted o n the efficacy of intramammary ampicillin (as the sole treatment) for clinical mastitis. Ampicillin in combination with other antibiotics has been repor ted t o be inferior to other intramammary preparations. However, when the ampicillin and cloxacillin preparation was compared only to itself with no controls, the results looked a lot better. When the same ampicillin/cloxacillin preparation was compared to either par ent era l cefquino me therapy, with or without intramammary cefquino me (cures of 82.6 to 95.2%), against expe riment ally induced E. coli, results indicated that the ampicillin product (cures of 54.5%) was significantly inferior. This study supports the lack of efficacy of amp icillin and cloxacillin in the treatment of clinical coliform mastitis in dairy cows.
So what criteria must a practitioner use to justify extralabel use in a situation where the [approved] dru g is ine ffect ive? There is nothing in the reg ulat ions to guid e vet erinarians in making this assessment. FDA recognizes that it is t he pr ofessional judgment o f a veterinarian to make that determination. Veterinarians aren't required to state their crit eria as to why they thought the drug was ineffective but economics should not be used as justificatio n of ELDU .
So is the extralabel intramammary use of ceftiofur effective for seve re c linical E. coli mastitis? Yes, it is. Figure 1 indic ates t he da ily colony forming units (cfu) for the case presented. The first two data po ints were prior to any intramammary ceftiofur. The third data point was after the first treatment and a lthough it appears there was no effect on the cfu, cfu decreased. The cow was treated once on day 2, twice on day 3, twice on day 4 and once more on day 5. Only the case cow is presente d her e but this figure represents a typical cfu response of cows with coliform mastitis treated with intramammary ceftiofur.
